183 related articles for article (PubMed ID: 23861650)
1. Atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder. Systematic review of review papers 2009-2011. An update for clinicians.
Bushe CJ; Savill N
J Cent Nerv Syst Dis; 2011; 3():209-17. PubMed ID: 23861650
[TBL] [Abstract][Full Text] [Related]
2. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety.
Bushe CJ; Savill NC
J Psychopharmacol; 2014 Mar; 28(3):204-11. PubMed ID: 23438503
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?
Savill N; Bushe CJ
Child Adolesc Psychiatry Ment Health; 2012 Jan; 6(1):2. PubMed ID: 22234242
[TBL] [Abstract][Full Text] [Related]
4. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
[TBL] [Abstract][Full Text] [Related]
5. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
[TBL] [Abstract][Full Text] [Related]
6. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of pharmaceutical therapy of ADHD (Attention-Deficit/Hyperactivity Disorder) in adults - health technology assessment.
Benkert D; Krause KH; Wasem J; Aidelsburger P
GMS Health Technol Assess; 2010 Sep; 6():Doc13. PubMed ID: 21289886
[TBL] [Abstract][Full Text] [Related]
8. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
9. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
[TBL] [Abstract][Full Text] [Related]
10. A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain.
Hong J; Dilla T; Arellano J
BMC Psychiatry; 2009 Apr; 9():15. PubMed ID: 19366449
[TBL] [Abstract][Full Text] [Related]
11. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
[TBL] [Abstract][Full Text] [Related]
12. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
13. Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-deficit hyperactivity disorder : clinical approaches and review of current available evidence.
Prasad S; Steer C
Paediatr Drugs; 2008; 10(1):39-47. PubMed ID: 18162007
[TBL] [Abstract][Full Text] [Related]
14. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis.
Rezaei G; Hosseini SA; Akbari Sari A; Olyaeemanesh A; Lotfi MH; Yassini M; Bidaki R; Nouri B
Med J Islam Repub Iran; 2016; 30():325. PubMed ID: 27390695
[TBL] [Abstract][Full Text] [Related]
16. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
17. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Gibson AP; Bettinger TL; Patel NC; Crismon ML
Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
[TBL] [Abstract][Full Text] [Related]
18. Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta-analysis of atomoxetine and methylphenidate comparator clinical trials.
Bushe CJ; Savill NC
Child Adolesc Psychiatry Ment Health; 2013; 7():19. PubMed ID: 23777626
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder (ADHD): a comprehensive meta-analysis of outcomes on parent-rated core symptomatology.
Gayleard JL; Mychailyszyn MP
Atten Defic Hyperact Disord; 2017 Sep; 9(3):149-160. PubMed ID: 28110366
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.
Savill NC; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill D
CNS Drugs; 2015 Feb; 29(2):131-51. PubMed ID: 25698145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
